Key Takeaways
- “Stem cells” are not one treatment. Blood-forming, mesenchymal, neural, retinal and pluripotent stem-cell-derived products differ in source, biological behaviour, manufacture, intended tissue and risk.
- Established haematopoietic stem-cell transplantation, a narrowly labelled approved cell product, a registered clinical trial and an unproven commercial injection are four different categories.
- In China, a stem-cell clinical-research filing is not marketing approval. Under the 2015 rules, filed research may not advertise itself as treatment or charge participants for research-related costs, and completing it does not directly convert it into routine clinical use.
- Credible evidence is disease-, cell-, product-, route- and endpoint-specific. Testimonials, laboratory papers, patents, conference posters and registry entries cannot by themselves prove patient benefit.
- Refusal to name the cell source, manufacturer, batch-release tests, approval or protocol number, adverse-event plan and long-term follow-up is a reason to stop—not a minor paperwork problem.
Content
The most useful first question is not “Do stem cells work?” It is: what exact cell product, for which diagnosis, through which regulated pathway, compared with what, and measured by which patient outcome?
Stem cells can self-renew and generate specialised cells, but that property does not make every preparation regenerative. The ISSCR patient guide separates established or approved treatments, investigational interventions in properly regulated trials and unproven products sold outside those systems [1]. A website may blur all three by calling an injection “innovative,” “hospital-developed” or “personalised.” Patients should not.
Begin with four separate categories
Category · What must be verified · What the category does not prove
Established clinical technology · disease indication, centre capability, donor/cell source and current clinical standards · that the same cells treat unrelated diseases
NMPA-approved product · exact generic name, approval number, current Chinese label, manufacturer, age and indication · approval of off-label diseases, routes or doses
Investigational research · official registration, sponsor, protocol, site, cohort, ethics approval and consent · effectiveness or eventual approval
Unproven commercial intervention · usually lacks a coherent regulatory and evidence file · safety merely because cells are autologous or “natural”
Haematopoietic stem-cell transplantation is an established technology for selected blood, immune and metabolic disorders. It has conditioning, donor selection, graft-versus-host disease, infection, graft failure and centre-quality requirements; it is not a general anti-ageing or tissue-repair injection. China’s 2022 restricted-technology standard sets minimum institutional, personnel and quality-management requirements for allogeneic haematopoietic transplantation [2].
Product approval is equally narrow. Amimestrocel injection, for example, was conditionally approved by the NMPA for steroid-refractory acute graft-versus-host disease with predominant gastrointestinal involvement in patients aged 14 years and older [3]. This is evidence for that labelled product and population—not proof that any mesenchymal-cell preparation treats arthritis, autism, stroke, diabetes, infertility or ageing.
Put a name and chain of custody on the cells
Ask the provider to state, in writing:
- autologous or donor-derived;
- tissue source: bone marrow, mobilised blood, cord blood, adipose tissue, placenta, embryo-derived line, induced pluripotent stem-cell line or another source;
- actual therapeutic cell type and degree of differentiation;
- collection and donor-screening process;
- whether cells are isolated, selected, cultured, expanded, genetically modified, differentiated, frozen or pooled;
- manufacturing site, responsible legal entity and transport conditions;
- route, dose, number of administrations and accompanying procedure;
- batch number and traceability from donor or collection to recipient.
“Umbilical,” “young,” “autologous” and “medical-grade” are descriptions, not release specifications. Exosomes are cell-derived particles, not stem cells; platelet-rich plasma is neither a stem-cell product nor proof of regeneration. A clinic that uses these terms interchangeably has not described the intervention.
For a living-cell product, identity and quality can change with tissue source, donor, passage number, culture conditions, cryopreservation and thawing. The file should address identity, purity, viability, cell number, sterility, mycoplasma, endotoxin, adventitious agents, potency, genetic stability where relevant and rules for an out-of-specification batch. China’s CDE guidance specifically recognises the heterogeneity and manufacturing complexity of human stem-cell products [4]. A glossy “laboratory certificate” without methods, limits, dates and batch linkage is not enough.
In China, identify the regulatory route before discussing benefit
There are two commonly confused research routes.
One is medical-institution stem-cell clinical research under the National Health Commission and drug regulator’s 2015 measures. The institution and project require review, filing, quality control, ethics oversight and public disclosure. The measures state that institutions may not charge participants stem-cell research-related fees or advertise the research, and that completing filed research does not directly authorise clinical application [5]. They also exclude already-regulated unmanipulated haematopoietic stem-cell transplantation and drug-registration trials from that particular framework.
The other is a stem-cell product developed as a drug through the NMPA clinical-trial and registration pathway. Its sponsor, investigational product, trial authorisation, protocol and registration should be identifiable. CDE’s 2023 clinical guidance addresses trial planning, design, implementation and analysis for human stem-cell and stem-cell-derived products [6].
For either route, obtain:
- the full protocol title and official registration number;
- the route—filed stem-cell clinical research or drug-registration trial;
- sponsor and manufacturer, not only the recruiting intermediary;
- hospital, department, principal investigator and active cohort;
- current ethics approval and participant-information version;
- who pays for product, tests, travel, standard care and research injury;
- stopping rules, emergency cover and long-term follow-up.
China’s 2024 investigator-initiated clinical-research rules require institutional approval, ethics review and registration in the national medical-research filing system [7]. A hospital logo, ethics stamp or registry entry proves only part of governance; none proves that the intervention works.
Read the evidence in the right order
Marketing often begins with a biological story: cells “home” to injury, reduce inflammation or replace damaged tissue. A plausible mechanism is a reason to test a treatment, not a clinical result.
Review evidence in this order:
- Exact match: Is the studied cell product made the same way, delivered by the same route and used for the same disease stage?
- Study design: Was there randomisation, an appropriate comparator, masking where feasible and prospectively specified analysis?
- Outcome: Did the study measure survival, function, symptoms or another meaningful endpoint rather than only a biomarker or scan?
- Size and duration: Were enough participants followed long enough to detect benefit, relapse and delayed harm?
- Completeness: Are withdrawals, deaths, serious adverse events and failed cell manufacture included?
- Reproducibility: Is there confirmation beyond one uncontrolled clinic series?
- Regulatory conclusion: Does the current label support the claim, or is the treatment still investigational?
A trial registration shows that someone declared a study. A peer-reviewed phase I paper may show feasibility or an initial safety profile. Neither equals confirmation of effectiveness. “Published,” “patented,” “used in thousands” and “no complaints” answer different questions and cannot replace controlled disease-specific data.
Be cautious with before-and-after videos. Symptoms fluctuate; rehabilitation, steroids, surgery, placebo effects and selective reporting can all create improvement that is wrongly attributed to cells. Ask for the denominator: how many people were treated, how many were evaluable, how many improved, for how long, and what happened to everyone else?
Risk follows the product and the route
Possible harms include contamination and infection, infusion or immune reactions, rejection, alloimmunisation, thrombosis or embolic events, ectopic tissue formation, unwanted differentiation, excessive cell growth and tumour formation. The conditioning drugs, immunosuppression, anaesthesia or catheter procedure may add more risk.
Route matters. An intraocular injection can threaten vision; intrathecal administration can cause neurologic or infectious complications; intra-arterial or intravenous cells may obstruct vessels or lodge outside the intended tissue. “No surgery” does not mean low risk.
The US FDA has documented blindness, tumours, infections and other serious events after unapproved regenerative products and warns that autologous origin does not exempt a product from safety concerns [8]. Those US regulatory statements do not determine Chinese approval, but the biological hazards are relevant when a provider claims that cells are harmless because they came from the patient or a newborn tissue.
Long-lived or proliferating cells can create delayed effects. The follow-up plan should state which examinations, laboratory tests, imaging and tumour surveillance are required; for how many years; who receives adverse-event reports; and what happens if the sponsor, manufacturer or site closes.
Common marketing red flags
- one preparation is offered for many unrelated neurologic, orthopaedic, immune, reproductive and anti-ageing indications;
- the salesperson gives a dose and price before a disease specialist reviews the record;
- “100% safe,” “guaranteed regeneration,” “no rejection” or a fixed improvement percentage;
- cells are described only as “umbilical,” “mesenchymal,” “NK,” “secretome” or “exosomes”;
- an overseas registry, patent or laboratory accreditation is presented as Chinese treatment approval;
- no Chinese generic name, NMPA number, protocol number or filing route;
- no comparator data, only testimonials, celebrity cases or microscopy images;
- cash or personal-account payment, expiring discounts or pressure to hide the treatment from the home doctor;
- research participants are charged a package price for the investigational stem-cell intervention without a defensible written allocation;
- no product-release certificate tied to the patient’s batch;
- no written plan for failed manufacture, acute complications or years of follow-up;
- optional add-ons multiply after arrival—exosomes, immune cells, “detox,” hyperbaric oxygen or supplements—without separate evidence.
Several red flags together should end payment and travel planning. A second opinion should come from a specialist who is independent of the clinic and has access to the protocol, product identity and complete evidence—not from another salesperson in the same organisation.
Build a one-page verification sheet
Before signing or paying, record:
Field · Required answer
Diagnosis and goal · exact diagnosis, stage, current standard options and measurable target
Product · cell type, source, donor/autologous status, manipulation, manufacturer and batch
Legal route · approved label, filed research or NMPA drug trial
Evidence · exact product/disease studies, comparator, primary outcome and follow-up
Delivery · dose, route, schedule, conditioning and procedure team
Quality · identity, viability, purity, potency, sterility and release rules
Safety · known/possible harms, stopping rules, emergency hospital and injury cover
Continuity · written records, home-team handover and long-term contact
Money · itemised research, standard-care, travel and complication costs
If a provider cannot complete this page, the uncertainty is not ready to be priced.
Cross-border patients need an exit plan
Confirm what happens if screening fails, cells cannot be collected, the batch fails release, disease progresses during manufacture or the patient becomes too unwell to travel. Deposits and refund terms should cover each branch.
Before leaving China, obtain the product and batch identity, cell source, dose and route, conditioning or immunosuppression, procedure note, laboratory trends, adverse events, culture results if relevant, discharge medicines, restrictions, emergency signs and follow-up calendar. The home clinician also needs a direct medical contact—not only a coordinator’s messaging account.
Do not stop a proven treatment merely to qualify for an unproven intervention unless the responsible disease specialist explains the consequences in writing. Lost time, lost trial eligibility and financial harm are part of the risk assessment.
Medical disclaimer: This guide is educational. It does not determine whether a stem-cell product is approved, establish trial eligibility or recommend treatment. Verify the current Chinese label or protocol and seek independent review from the relevant disease specialist, a transplant or cell-therapy team and, when needed, a clinical-trials pharmacist or research office.
FAQ
Are all stem-cell treatments experimental?
No. Haematopoietic stem-cell transplantation is established for selected disorders, and individual stem-cell products may have narrow regulatory approvals. Many other uses remain investigational or unproven; the exact product and indication determine the category.
Does using my own cells make the treatment safe?
No. Autologous cells can still be contaminated, altered during culture, delivered to the wrong site, form unwanted tissue or cause procedure-related harm. Product processing and intended use still matter.
Does registration on a clinical-trial website prove effectiveness?
No. Registration identifies a declared study and helps verify its protocol. Effectiveness requires interpretable results from appropriate studies and, for routine sale, the relevant regulatory approval.
Should a participant pay for stem-cell clinical research in China?
Under China’s 2015 filed stem-cell clinical-research route, institutions may not charge participants research-related fees. Drug trials and ordinary medical care have separate cost rules. Obtain a written itemisation and ask the institution’s research office to explain any charge.
What is the strongest sign that an offer is credible?
There is no single badge. Credibility comes from a consistent chain: exact diagnosis, named product, legitimate route, independent review, disease-specific evidence, batch quality controls, honest uncertainty, emergency capacity and long-term follow-up.
Sources
- International Society for Stem Cell Research — Guide to Stem Cell Treatments, 2024
- National Health Commission — Allogeneic Haematopoietic Stem-Cell Transplantation Standard, 2022
- National Medical Products Administration — Conditional Approval of Amimestrocel Injection
- Center for Drug Evaluation — Pharmaceutical Research and Evaluation of Human Stem-Cell Products
- National Health Commission — Administrative Measures for Stem-Cell Clinical Research
- Center for Drug Evaluation — Clinical Trials of Human Stem-Cell and Derived-Cell Products
- National Health Commission — Management of Investigator-Initiated Clinical Research
- US Food and Drug Administration — Patient Information on Regenerative Medicine Therapies
Image Review
- Decision: Approved after editorial review; copied as hero-reviewed.png.
- Editorial note: The cell symbol, safety shield, checklist, evidence balance and advertising megaphone directly support the article’s verification theme. It is a conceptual illustration, not microscopy, a product certificate or proof of efficacy.